We manufactures Montelukast Sodium. It is mainly used to treat nasal congestion, but may also be useful in discussing hypotension and shock, hypotension during spinal anesthesia. Phenylephrine HCL
Peter Handscomb
Related Articles
Poonam 2023-12-22
The global ticagrelor market is estimated to be valued at US$ 1285. As ticagrelor is extensively used for treatment of patients with acute coronary syndromes and myocardial infarction, high disease prevalence is likely to propel the demand for ticagrelor over the forecast period. Competitive rivalry: The competitive rivalry is high among the major players operating in the ticagrelor market. Key Takeaways The global Ticagrelor Market Growth is expected to witness high growth over the forecast period of 2023-2030 driven by rising prevalence of cardiovascular diseases. The global ticagrelor market is estimated to be valued at US$ 1285. Key players operating in the ticagrelor market are ANDRITZ Group, Baltur S.
0
samruddhicmi12 2023-12-07
The Global Ticagrelor Market is estimated to be valued at US$ 1285. According to World Health Organization, cardiovascular diseases are the leading cause of death globally, taking an estimate of over 17. Segment AnalysisThe global ticagrelor market is segmented by dosage, application, distribution channel, and region. Geographically, North America holds the largest share in the ticagrelor market due to growing initiatives by healthcare organizations to spread awareness regarding antiplatelet treatment options. AstraZeneca's Brilinta is the leading brand in the global ticagrelor market.
0
Pratik 2024-03-13
The global ticagrelor market is estimated to be valued at US$ 1481. Key TakeawaysKey players operating in the Ticagrelor Market Demand are Atlas Roofing Corporation, BASF SE, Johns Manville, Duro-Last, Inc. Growing prevalence of cardiovascular diseases and increasing demand for effective antiplatelet drugs post procedures such as angioplasty and stenting are expected to create significant growth opportunities for players in the global ticagrelor market. Growing burden of diseases like diabetes and obesity which are contributors to cardiovascular conditions is anticipated to propel the demand for antiplatelet drugs like ticagrelor over the forecast period. This large patient pool and enhanced efficacy over alternatives drives the growth of the ACS sub segment of the ticagrelor market.
0
Pooja salve 2023-04-03
It has a moderate duration of action because it is used twice day, and it has a broad therapeutic index because high single doses are easily tolerated. It has a half-life of approximately 7 hours, which means that it is cleared from the body relatively quickly. In the PLATO trial, which compared ticagrelor to clopidogrel in over 18,000 patients with ACS, ticagrelor was found to be superior in reducing the incidence of cardiovascular death, heart attack, and stroke. Like all medications, ticagrelor can cause side effects. The most common side effects of ticagrelor include bleeding, shortness of breath, and nausea.
0
Mia Yates 2024-01-24
The Global Ticagrelor Market Size is estimated to be valued at US$ 1481. This has significantly contributed to the growth of the ticagrelor market over the forecast period. Segment Analysis The global ticagrelor market is dominated by the hospital pharmacy sub-segment. Regional analysis North America currently dominates the ticagrelor market and is expected to continue its leading position through 2031. Additionally, favorable reimbursement environment for novel drugs in the US and Canada is boosting market growth.
0
MrMed Pharmacy 2024-01-24
In the article, Let us explore the causes, risk factors, management, and preventive strategies for acute coronary syndrome (ACS). This syndrome often causes chest pain, while some people won't experience chest pain at all. Beta-blockers (regulate BP)Nitroglycerin (relieves chest pain and improves blood flow)Statins ( reduce blood cholesterol level)Thrombolytic medications (dissolve blood clots)2. Aspirin Use: Low-dose aspirin for preventing heart disease has become more selective and should be based on a risk-benefit assessment with your doctor. Pharmacological Therapy: i.
0
WHO TO FOLLOW